Stock AnalizZymeworks Inc. ZYME
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Zymeworks Inc. (ZYME) is a healthcare company listed in the US with a market value of about $1.8B. In the twelve months to September 30, 2026 it had revenue of $266M and net income of $43M, a net margin of 16.3%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a P/E of 50.5, 5-year revenue growth of 22% a year, a 5-year average ROIC of -27%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 76% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $266M | $106M | $76M | $76M | $412M | $27M | $39M |
| Net income | $43M | -$81M | -$123M | -$119M | $124M | -$212M | -$181M |
| Free cash flow | -$113M | -$35M | -$112M | -$121M | $136M | -$205M | -$156M |
| EPS (diluted) | $0.52 | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 | $-3.58 |
| Net margin | 16.3% | -76.6% | -160.8% | -156.1% | 30.1% | -794.0% | -463.5% |
| ROIC | — | -25.5% | -30.3% | -28.0% | 23.0% | -76.5% | -36.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $43.29, 65% above the current price; targets range from $35.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $1.51 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Zymeworks’s P/E ratio?
About 50.5, based on the last twelve months of diluted earnings per share (forward P/E about 11.0).
Is Zymeworks stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 76% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Zymeworks pay a dividend?
Not currently.
Is Zymeworks a good stock to buy?
We do not give buy or sell advice. Zymeworks scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.